funded by the National Natural Science Foundation of China grant 81700148 and Natural Science Foundation of Guangdong Province grant 2021A1515010093 and 2023A1515011862;funded by the National Natural Science Foundation of China grant 82170181;funded by the Basic and Applied Basic Research Foundation of Guangdong Province grant 2022B1515120087.
Objectives:The optimal treatment strategy for early-stage natural killer/T-cell lymphoma(NKTCL)remains unclear.This study aimed to evaluate and compare the clinical outcomes and adverse events(AEs)associated with two ...
National Natural Science Foundation of China(81972232,81830102,82150004);Clinical Research Plan of SHDC(SHDC‑2020CR1003A,SHDC-2020CR1022B);National Key Research and Development Program of China(2019YFC1316000,2019YFC1315800,and 2019YFC1315802);the Key Disease Joint Research Program of Xuhui District(XHLHGG202103),the Clinical Medicine Research Pilot Project of Shanghai Medical School of Fudan University(2020,21DGF501035/00);the Shanghai Municipal Natural Science Foundation(20JC1419103,21ZR1412200);Beijing Mutual Care Public Welfare Foundation(GDXZ-08-05)Sanming Project of Medicine in Shenzhen(SZSM202003009),and Shanghai Municipal Key Clinical Specialty Construction Project(shslczdzk02401).
Advanced intrahepatic cholangiocarcinoma(ICC)has a dismal prognosis.Here,we report the efficacy and safety of combining toripalimab,lenvatinib,and gemcitabine plus oxaliplatin(GEMOX)as first-line therapy for advanced ...